Ursheet Parikh, partner at Mayfield and investor in Mammoth Biosciences, traces the evolution of life sciences tech companies that led to the trend of startups focused on creating assets for large pharmaceutical companies to buy. He describes how Mammoth, in contrast, built a platform-based company from the start, guided by their mission to impact and save as many lives as possible.
Related
Josh Wolfe,
Lux Capital
Investing at the Cutting Edge [Entire Talk]
The entrepreneurs that attract venture capital investments think differently and tackle big problems that few others are willing to
Josh Wolfe,
Lux Capital
Investing at the Cutting Edge [Entire Talk]
The entrepreneurs that attract venture capital investments think differently and tackle big problems that few others are willing to
Rahul Roy-Chowdhury,
Grammarly
Responsible AI Innovation [Entire Talk]
AI tools are the future of technology. People have the power to ensure AI benefits us.
Rahul Roy-Chowdhury,
Grammarly
Responsible AI Innovation [Entire Talk]
AI tools are the future of technology. People have the power to ensure AI benefits us.
Claire Hughes Johnson,
Stripe
Scaling Operations and People [Entire Talk]
Build a company that is ready to scale with a strong foundation of values, well-built operating structures, and a complementary team.
Claire Hughes Johnson,
Stripe
Scaling Operations and People [Entire Talk]
Build a company that is ready to scale with a strong foundation of values, well-built operating structures, and a complementary team.
